Rockefeller Capital Management L.P. Has $9.05 Million Stake in Agilent Technologies, Inc. $A

Rockefeller Capital Management L.P. lowered its holdings in Agilent Technologies, Inc. (NYSE:A) by 6.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,495 shares of the medical research company’s stock after selling 4,570 shares during the period. Rockefeller Capital Management L.P.’s holdings in Agilent Technologies were worth $9,048,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Core Wealth Advisors LLC bought a new stake in Agilent Technologies during the fourth quarter worth about $26,000. SHP Wealth Management bought a new position in Agilent Technologies in the fourth quarter valued at approximately $26,000. Board of the Pension Protection Fund bought a new position in Agilent Technologies in the fourth quarter valued at approximately $27,000. Navalign LLC acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $27,000. Finally, MV Capital Management Inc. acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $28,000.

Agilent Technologies News Roundup

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent completed its acquisition of Biocare Medical, adding immunohistochemistry, in situ hybridization and fluorescence in situ hybridization solutions to its portfolio, which could support longer-term revenue growth and cross-selling opportunities. Article Title
• Positive Sentiment: Barclays raised its price target on Agilent and reiterated an overweight view, signaling Wall Street sees additional upside from current levels. Article Title
• Neutral Sentiment: Piper Sandler initiated coverage with a neutral rating and a $150 price target, which supports valuation but is not an outright bullish call. Article Title
• Neutral Sentiment: Agilent also announced that Shanghai ICRD adopted its software, a modest business win that reinforces demand for its lab and workflow tools. Article Title

Agilent Technologies Trading Up 3.1%

Shares of Agilent Technologies stock opened at $135.73 on Friday. The business has a fifty day simple moving average of $122.53 and a two-hundred day simple moving average of $126.25. Agilent Technologies, Inc. has a 1 year low of $108.35 and a 1 year high of $160.27. The company has a market capitalization of $38.33 billion, a price-to-earnings ratio of 27.25, a P/E/G ratio of 2.34 and a beta of 1.26. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.10 and a quick ratio of 1.62.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.08. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The firm had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the previous year, the business posted $1.31 earnings per share. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Research analysts forecast that Agilent Technologies, Inc. will post 6 EPS for the current year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Tuesday, June 30th will be issued a dividend of $0.255 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $1.02 annualized dividend and a dividend yield of 0.8%. Agilent Technologies’s payout ratio is presently 20.48%.

Analysts Set New Price Targets

A has been the subject of several recent analyst reports. Royal Bank Of Canada started coverage on Agilent Technologies in a report on Wednesday, May 27th. They issued an “outperform” rating and a $153.00 price objective for the company. Weiss Ratings raised shares of Agilent Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 2nd. Wolfe Research reiterated a “hold” rating on shares of Agilent Technologies in a research note on Tuesday, June 2nd. Bank of America upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and cut their price target for the company from $150.00 to $145.00 in a research note on Thursday, May 28th. Finally, HSBC decreased their price objective on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $161.27.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.